Skip to main content
Caplight Logo









LynxDx

LynxDx

Private
Ann Arbor, MichiganHealthcare & Life Scienceshttps://www.lynxdx.com/

Last Round

Grant

Sep 1, 2020

Total Funding Raised

$3.95M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

LynxDx is a biotechnology company that develops innovative diagnostic solutions, including the MyProstateScore (MPS) urine test for prostate cancer risk assessment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

prostate cancer screeninggenomic diagnostic testliquid biopsyMyProstateScoreMPSnon-invasive diagnosticsprostate cancer risk assessmentprecision medicinebiomarker testurology diagnosticsactive surveillancepredictive algorithmclinical laboratorydiagnostic assay

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LynxDx Comparables

Compare LynxDx with similar companies based on industry and business-model similarity.

LynxDx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MiRNA Scientific
86%
NucleoBio Corp
83%
MDxHealth
80%

LynxDx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 1, 2020
GrantJun 15, 2020
SeedJan 1, 2020
GrantSep 23, 2019

Key People

Founding team and executive leadership

Jeff Crays

Chief Technology Officer

Executive Team

Mark Willig

Advisory Board Member and Chief Commercial Officer (CCO)

Executive Team

LynxDx Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Monthly visitors increased 32% MoM.

  • Mar 5, 2026

    Monthly visitors increased 81% MoM, reaching 8.5K.

LynxDx Filings

Explore SEC and related filing metadata, where available.

LynxDx filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about LynxDx's valuation, stock price, and market status.

Is LynxDx a public or private company?

LynxDx is a private company.

What is the current stock price of LynxDx?

LynxDx is a private company with no public stock price. No recent secondary market data is available.

How much is LynxDx worth (valuation)?

Valuation information for LynxDx is not publicly available.

Can I buy LynxDx stock?

LynxDx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was LynxDx's last funding round?

LynxDx's most recent funding round was Grant on September 1, 2020.

Who are the main investors in LynxDx?

Key investors in LynxDx include National Cancer Institute, Innovation Partnerships, ID Ventures, National Institutes of Health (NIH).

Will LynxDx IPO soon?

No public IPO plans have been announced for LynxDx.

How can I track LynxDx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor LynxDx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAnn Arbor, Michigan
Employee Range67
Year Founded2019
Last FundingSep 1, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?